Rocket Pharma | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.45, beating the estimate of USD -0.5044.

EBIT: As of FY2025 Q3, the actual value is USD -52.25 M.

Financial Metrics by Segment

Cash Position

• Cash, cash equivalents, and investments as of September 30, 2025, were $222.8 million. Rocket expects these resources, excluding any potential future proceeds from a Priority Review Voucher that may be granted upon FDA approval of KRESLADI™, will be sufficient to fund its operations into the second quarter of 2027.

Research and Development (R&D) Expenses

• R&D expenses were $34.1 million for the three months ended September 30, 2025, compared to $42.3 million for the three months ended September 30, 2024. The decrease of $8.2 million was primarily driven by decreases in manufacturing and development and direct material costs of $3.6 million, clinical trial expenses of $2.4 million, and professional fees of $2.0 million.

General and Administrative (G&A) Expenses

• G&A expenses were $18.4 million for the three months ended September 30, 2025, compared to $27.1 million for the three months ended September 30, 2024. The decrease of $8.7 million was primarily driven by decreases in commercial preparation-related expenses of $6.6 million and non-cash stock-based compensation expense of $1.5 million.

Net Loss

• Net loss was $50.3 million or $0.45 per share (basic and diluted) for the three months ended September 30, 2025, compared to $66.7 million or $0.71 (basic and diluted) for the three months ended September 30, 2024.

Shares Outstanding

• 108,208,643 shares of common stock were outstanding as of September 30, 2025.

Restructuring Expenses

• Approximately $3.3 million in restructuring and restructuring-related charges were incurred in 2025.

Outlook / Guidance

• Rocket Pharmaceuticals expects its cash, cash equivalents, and investments to be sufficient to fund its operations into the second quarter of 2027.
• The pivotal Phase 2 trial of RP-A501 for Danon disease is anticipated to resume in the first half of 2026.
• KRESLADI™ for severe LAD-I is on track for a March 28, 2026, PDUFA date.